TVTX Q1 2021 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$47M-0.8% YoY

Gross Profit

$46M96.5% margin

Operating Income

-$48M-100.3% margin

Net Income

-$54M-113.6% margin

EPS (Diluted)

$-0.96

QoQ Revenue Growth

-7.0%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$36M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$764M

Total Liabilities

$401M

Stockholders' Equity

$363M

Cash & Equivalents

$148M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$47M	$48M	-0.8%
Gross Profit	$46M	$46M	-1.4%
Operating Income	-$48M	-$15M	-215.6%
Net Income	-$54M	$808,000	-6766.7%

Revenue Segments

Tiopronin Products

$25M54%

Bile Acid Products

$22M46%